Filing identity and reporting period
Important: The supplied filing is Zafgen, Inc.’s Form 10-K for the fiscal year ended December 31, 2015, filed March 15, 2016. It is not a Larimar Therapeutics filing. The filing also provides unaudited quarterly results, including the three months ended December 31, 2015.
Zafgen was a development-stage biopharmaceutical company focused on MetAP2 inhibitors for obesity and metabolic disorders. It had no approved products or product-sale revenue.
Financial performance and position
| Metric | FY 2015 | FY 2014 |
|---|---|---|
| Revenue | $0 | $0 |
| Research and development expense | $54.6 million | $27.4 million |
| General and administrative expense | $19.2 million | $8.1 million |
| Total operating expenses | $73.8 million | $35.5 million |
| Net loss | $74.3 million | $36.5 million |
| Net loss per share, basic and diluted | $2.78 | $3.00 |
| Cash, cash equivalents and marketable securities at year-end | $185.1 million | $115.5 million |
| Working capital at year-end | $171.6 million | $110.3 million |
| Notes payable at year-end | $6.4 million carrying value | $7.6 million carrying value |
Operating cash use was $59.6 million in 2015, versus $28.2 million in 2014. Investing activities used $92.1 million, primarily reflecting purchases of marketable securities, while financing activities provided $129.2 million, mainly from a January 2015 follow-on offering. The company reported no revenue, so operating margins are not meaningful. Its $74.3 million net loss widened from 2014; the larger share count following equity financings reduced the reported per-share loss.
Cash and marketable securities were mostly invested in money market funds, U.S. government securities, corporate bonds and commercial paper. Management estimated available funds would support operations for at least 18 months from year-end 2015, subject to assumptions and operating-plan changes. The outstanding credit facility bore stated interest of 8.1% and had an effective annual rate of approximately 10.8%; scheduled principal repayments were $2.9 million in 2016 and $3.2 million in 2017. Operating lease commitments totaled $0.9 million.
Material changes and operating developments
- Operating expenses more than doubled year over year. R&D rose $27.2 million, reflecting clinical activity, manufacturing and toxicology work, and increased investment in ZGN-839 and second-generation MetAP2 inhibitors. G&A increased $11.1 million, including higher stock compensation, professional fees and staffing.
- R&D spending was $29.6 million for beloranib, $4.9 million for ZGN-839, $5.8 million for second-generation MetAP2 inhibitors and $14.4 million of unallocated expenses.
- The January 2015 follow-on offering generated approximately $129.6 million in net proceeds. Shares outstanding increased to 27.2 million at year-end from 22.9 million.
- Unaudited Q4 2015 operating expenses were $23.2 million and net loss was $23.2 million, compared with Q4 2014 operating expenses of $10.7 million and net loss of $10.9 million.
Outlook, risks and unusual items
- Beloranib clinical hold: In December 2015, the FDA placed the beloranib IND on full clinical hold following an imbalance in thrombotic events, including two pulmonary-embolism deaths in beloranib-treated patients. The company could not assure the hold would be lifted. It planned to submit trial data and a proposed risk-mitigation strategy and seek an FDA Type A meeting. Further PWS Phase 3 testing was anticipated if development could resume.
- Efficacy versus safety: The company reported in January 2016 that its first PWS Phase 3 trial met co-primary endpoints for weight and hyperphagia-related behaviors. In February 2016, it reported that the Phase 2b trial in severe obesity with type 2 diabetes met its weight-loss endpoint and showed a 2.0 percentage-point HbA1c reduction in treated groups versus 0.6 points for placebo. These results do not resolve the safety concern or establish regulatory approval.
- Pipeline uncertainty: ZGN-839 was preclinical; its IND was withdrawn in January 2016 to generate additional thrombosis-risk data. Other second-generation candidates also remained preclinical. The company cautioned that MetAP2 inhibitors could share thrombotic risk.
- Funding and execution: Zafgen expected continued losses and rising development costs and stated it would need additional capital to obtain approvals and commercialize products. Financing might be unavailable or dilutive. It relied on contract manufacturers and CROs, and the beloranib manufacturing process was not yet validated.
- Legal contingency: A putative securities class action alleged misleading disclosures about beloranib trials. The company had not filed a responsive pleading and stated that the possible loss could not be estimated; no accrual was recorded.
- Other items: The company identified an immaterial prior-period R&D tax-credit misstatement, corrected through revised disclosures with no effect on reported net deferred tax assets or tax provision. The auditor issued an unqualified opinion on the financial statements.
Most important facts for investors to verify
- Confirm the issuer identity: the supplied document is Zafgen, Inc., not Larimar Therapeutics, Inc.
- Review subsequent FDA decisions and whether the beloranib clinical hold was lifted, and assess the full thrombotic-event and mortality data.
- Check the complete trial results, analyses and regulatory status behind the reported PWS and type 2 diabetes efficacy findings.
- Validate the cash runway against later spending, financing, debt repayment and development plans; the 18-month estimate was management’s forecast, not a guarantee.
- Track the securities litigation, potential exposure and any later resolution or accrual.